Impact of the revised FIGO/WHO system on the management of patients with gestational trophoblastic neoplasia
Authors:
- B.W. HancockBHB.W. Hancock
- 1 June 2009
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 113 (3) , 306-311
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Evolution of treatment of high-risk metastatic gestational trophoblastic tumors: Ain Shams University experienceInternational Journal of Gynecological Cancer, 2006
- Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effectsBritish Journal of Cancer, 2003
- Gestational trophoblastic neoplasia, FIGO 2000 staging and classificationInternational Journal of Gynecology & Obstetrics, 2003
- FIGO staging for gestational trophoblastic neoplasia 2000International Journal of Gynecology & Obstetrics, 2002
- 5-Day Methotrexate for Women with Metastatic Gestational Trophoblastic DiseaseGynecologic Oncology, 1994
- Metastatic gestational trophoblastic disease: A comparison of prognostic classification systemsGynecologic Oncology, 1992
- Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989BJOG: An International Journal of Obstetrics & Gynaecology, 1991
- Risk factors in gestational trophoblastic disease, and consequences for primary treatmentEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 1986
- Treatment of metastatic trophoblastic disease: Good and poor prognosisAmerican Journal of Obstetrics and Gynecology, 1973
- Sequential use of methotrexate and actinomycin D in the treatment of metastatic choriocarcinoma and related trophoblastic diseases in womenAmerican Journal of Obstetrics and Gynecology, 1965